SCHEMBL16049203

SCHEMBL16049203

COc1nc(NC(C)C)ncc1-c1ccc(Oc2ccnc(NC(C)=O)c2)c(C)n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 11/20 0.68
▸ PDGFRA P16234 6/20 0.68
▸ PDGFRB P09619 3/20 0.68
▸ FLT3 P36888 4/20 0.44
▸ LCK P06239 1/20 0.44
▸ KIT P10721 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ PTK6 Q13882 1/20 0.44
▸ KDR P35968 1/20 0.43
▸ TGFBR1 P36897 3/20 0.39
▸ PIK3C3 Q8NEB9 1/20 0.38
▸ AAK1 Q2M2I8 3/20 0.37
▸ GAK O14976 1/20 0.37
▸ HTR2B P41595 1/20 0.37
▸ DAPK1 P53355 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ MKNK1 Q9BUB5 1/20 0.37
▸ MYLK2 Q9H1R3 1/20 0.37
▸ MKNK2 Q9HBH9 1/20 0.37
▸ BMP2K Q9NSY1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25912909 0.85 PDGFRB (0.50) CSF1RPDGFRAPDGFRBLCKKIT
SCHEMBL16048014 0.84 CSF1R (0.47) CSF1RPDGFRAPDGFRBFLT3LCK
SCHEMBL16046823 0.81 CSF1R (1.00) CSF1RPDGFRAPDGFRBFLT3LCK
SCHEMBL25913590 0.79 CSF1R (0.43) CSF1RPDGFRAPDGFRBAAK1BRAF
SCHEMBL16046249 0.78 CSF1R (0.70) CSF1RPDGFRAPDGFRBFLT3LCK
SCHEMBL16047862 0.76 CSF1R (0.69) CSF1RPDGFRAPDGFRBFLT3LCK
SCHEMBL25913006 0.76 CSF1R (0.40) CSF1RPDGFRAPDGFRBAAK1BRAF
SCHEMBL21824005 0.75 CSF1R (0.41) CSF1RPDGFRAPDGFRBFLT3LCK
SCHEMBL21824003 0.75 CSF1R (0.41) CSF1RPDGFRAPDGFRBFLT3LCK
SCHEMBL16046316 0.73 CSF1R (0.47) CSF1RPDGFRAPDGFRBFLT3LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107311981-B 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activity 德西费拉制药有限责任公司 2020-05-29 — — CN disclosed
EP-2968286-B1 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS LLC (US) 2017-09-13 — — EP disclosed
EP-2968286-A2 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES Deciphera Pharmaceuticals, LLC (US) 2016-01-20 — — EP disclosed
US-9181223-B2 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2015-11-10 — — US disclosed
US-20140275085-A1 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — US disclosed
WO-2014145025-A2 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275085-A1 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES CSF1R, KIT, CSF3R CSF1R 1/4885PDGFRA 6/4885PDGFRB 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback